TODAY: Save the Date: GBECAM Connection – May 6, 2025!
🌍 An exclusive session in English, with simultaneous translation (EN–PT) to make it accessible for all!
📅 Date: Tuesday, May 6, 2025
🕖 Time:
🇧🇷 7:00–8:30 PM (BRT)
🇮🇹 Milan: 11:00 PM (UTC+2)
🇺🇸 Boston: 6:00 PM (UTC-4)
📍 Where: Zoom
Topic: HER2-Low Landscape
Coordinator: Dr. Bruna Zucchetti @zucchetti_bruna
Speakers: Dr. Paolo Tarantino & Dr. Giuseppe Curigliano @PTarantinoMD@curijoey
Debaters: Dr. Rafael Kaliks & Dr. Jessé Lopes @KaliksRafael
Highlights:
🔹 How to treat ER+/HER2-neg mBC after 1L CDK4/6i (Curigliano)
🔹 ADC sequencing in ER+ HER2-neg mBC: 2025 & beyond (Tarantino)
🔹 Followed by a dynamic debate!
Sponsored by: @AstraZeneca
🔗 Join us!
https://t.co/4ul61YRlyM
New Brazilian real-world data from GBECAM members: only 58.7% of women with nonmetastatic ER+ breast cancer adhered to adjuvant endocrine therapy. Better QoL linked to better adherence. Urgent need for survivorship support.
🔗 Full text available
https://t.co/juTxJrM0HS
#BreastCancer #GBECAM
Great job! @assad_daniele@DrRBarroso
Convite para o Tumor Board do GBECAM
Temos o prazer de convidá-los para o Tumor Board do GBECAM, um evento dedicado à discussão multidisciplinar de casos em oncologia mamária. Esta iniciativa visa promover a colaboração entre especialistas para otimizar a tomada de decisões e proporcionar o melhor cuidado aos pacientes.
Detalhes do evento:
📌 Tema: Decisões de tratamento baseadas em painel genômico (ou na ausência dele)
📅 Data: 22/04/2025 (Terça-feira)
⏰ Horário: 19:00 - 20:30 (BRT)
🔗 Via Zoom
Coordenação:
🔹 Dra. Solange Sanches – Oncologista (SP) @DraSSanches
🔹 Dr. Cristiano Resende – Oncologista (DF) @crisonco
Moderação:
🔹 Dra. Martina Arenhardt @mparenhardt
Debatedores:
🔹 Dr. Francisco Pimentel – Mastologista (CE)
🔹 Dr. Leandro Jonata – Oncologista (SP) @LeandroJonatad1
🔹 Dr. Gustavo Nader – Radioterapeuta (SP)
🔹 Dra. Ruana Rocha – Patologista (CE) @RuanaRocha
🔗Acesse o link para se inscrever
https://t.co/tvtcq6yjZy
Amazing talk by @drsarahsam at @GBECAMConnect Conference last week! Thank you so much for such great discussions and insights for future plans. We'll be waiting for you in Recife next time around! 😎🏝️
A few highlights from my ADC resistance talk at @LACOG_group@GBECAMConnect
1) T-DXd works after T-DM1, diff payload, stronger ADC
2) 2nd TOP1 ADC performs inferiorly
3) Muts in TROP2 and TOP1--> resistance
4) ⬇️target occurs post T-DXd
5) New ADCs with diverse payloads needed
Best of SABCS 2024 – Advanced Breast Cancer 🧬 Featuring an amazing panel: @DGagliato , Carlos dos Anjos, Aline Gonçalves, Andrea Shimada, Otto Metzker & Gisah Guilgen! 💬✨
#BreastCancer#SABCS2024#Oncology
Maryam Lustberg @maryam_lustberg Chief of Breast Oncology and Director of the Breast Center at Yale Cancer Center in New Haven Connecticut) sharing insights on Optimizing Post-Cancer Life Management: challenges & strategies in the journey of patients with triple-negative breast cancer — joined by Maria Cristina Figueroa & @JulianaRBeal . Powerful session! @LACOG_group
#BreastCancer #TNBC #Survivorship
The largest Brazilian conference in breast cancer started today - @GBECAMConnect .
@itsnot_pink is giving us a lecture that comes with the most important lesson: nothing happens in oncology without the patient! They are why we do what we do 🤍
2025 is anticipated to be the year with the highest number of phase 3 ADC trials read outs in breast oncology, with impact for all breast cancer subtypes.
Here’s 8 ADC breast cancer trials expected to reshape practice in 2025:
Nos dias 28 e 29 de março de 2025, São Paulo será palco da Conferência Brasileira de Câncer de Mama LACOG - GBECAM 2025 (@LACOG_group@GBECAMConnect ). Garanta sua participação gratuita realizando a inscrição no site oficial:
https://t.co/DYgQdcZ8Ox.